公开(公告)号：US20140161887A1

公开(公告)日：2014-06-12

申请号：US14081986

申请日：2013-11-15

申请人： Novartis Vaccines and Diagnostics, Inc.

发明人： Derek O'Hagan ,  Nicholas Valiante

IPC分类号： A61K39/39

CPC分类号： A61K39/39 ,  A61K39/095 ,  A61K39/21 ,  A61K39/29 ,  A61K2039/55522 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55566 ,  C12N7/00 ,  C12N2740/16034 ,  C12N2770/24234

摘要： Adjuvant compositions comprising type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.

摘要翻译： 描述了包含1型干扰素诱导剂（例如双链RNA）与抗原递送系统和/或免疫刺激分子（例如免疫刺激性核酸序列）组合的辅助组合物，用于增强共同施用的抗原的免疫应答。

公开(公告)号：US20140099719A1

公开(公告)日：2014-04-10

申请号：US13893821

申请日：2013-05-14

申请人： Novartis Vaccines and Diagnostics, Inc.

发明人： Daniela Tornese Buonamassa ,  Catherine E. Greer ,  Cesira L. Galeotti ,  Giuliano Bensi ,  Roberto Petracca

IPC分类号： C12N15/81

CPC分类号： C12N15/81 ,  A61K2039/5258 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/20023 ,  C12N2800/102 ,  C12N2800/108

摘要： Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production of conformational antibodies against both L1 proteins upon administration to mice.

摘要翻译： 描述了来自不同病毒类型的病毒衣壳蛋白的马赛克VLP，以及制备相同的方法。 具体地说，描述了共表达HPV-6和HPV-16的L1和L2衣壳蛋白作为马赛克VLP的二倍体酵母菌株。 在施用于小鼠后，马赛克VLP诱导针对两种L1蛋白的构象抗体的产生。

公开(公告)号：US08568734B2

公开(公告)日：2013-10-29

申请号：US13426295

申请日：2012-03-21

申请人： Vega Masignani ,  Maria Scarselli ,  Barbara Capecchi ,  Victoria Sharma ,  Susan W Barnett ,  Indresh K. Srivastava ,  Rino Rappuoli

发明人： Vega Masignani ,  Maria Scarselli ,  Barbara Capecchi ,  Victoria Sharma ,  Susan W Barnett ,  Indresh K. Srivastava ,  Rino Rappuoli

IPC分类号： A61K39/00 ,  A61K39/21 ,  A61K38/00 ,  A61K39/02 ,  C07K1/00 ,  C07H21/04

CPC分类号： C07K14/70514 ,  C07K2319/01

摘要： Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.

摘要翻译： 描述了包含在非CD4主链中结合HIV Env多肽的CD4最小模块的融合蛋白。 还描述了这些融合蛋白与Env的复合物以及使用多核苷酸和多肽的诊断，治疗和预防的方法。

公开(公告)号：US20130196314A1

公开(公告)日：2013-08-01

申请号：US13565714

申请日：2012-08-02

申请人： Joerg Kaufmann ,  Greg Harrowe ,  Christoph Reinhard ,  Sanmao Kang

发明人： Joerg Kaufmann ,  Greg Harrowe ,  Christoph Reinhard ,  Sanmao Kang

IPC分类号： G01N33/574 ,  C12Q1/68

CPC分类号： G01N33/57484 ,  C07K14/47 ,  C07K14/4748 ,  C07K16/18 ,  C07K16/3015 ,  C07K2317/34 ,  C07K2319/00 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415

摘要： A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.

摘要翻译： 如SEQ ID NO：1所示的多核苷酸序列与癌细胞，特别是乳腺癌细胞的转移潜能相关。 通过确定来自肿瘤的组织样品是否表达由多核苷酸编码的多肽，如SEQ ID NO：1所示，提供了用于确定肿瘤转移风险的方法。 还提供了治疗方法和组合物。

公开(公告)号：US20130195898A1

公开(公告)日：2013-08-01

申请号：US13621174

申请日：2012-09-15

申请人： Derek O'Hagan ,  Gary S. Ott ,  John Donnelly ,  Jina Kazzaz ,  Mildred Ugozzoli ,  Manmohan Singh ,  John Barackman

发明人： Derek O'Hagan ,  Gary S. Ott ,  John Donnelly ,  Jina Kazzaz ,  Mildred Ugozzoli ,  Manmohan Singh ,  John Barackman

IPC分类号： A61K39/39

CPC分类号： A61K39/39 ,  A61K9/1075 ,  A61K9/167 ,  A61K39/0208 ,  A61K39/21 ,  A61K39/245 ,  A61K39/29 ,  Y02A50/411 ,  Y02A50/471

摘要： Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided. Methods of stimulating an immune response, methods of immunizing a host animal against a viral, bacterial, or parasitic infection, and methods of increasing a Th1 immune response in a host animal by administering to the animal an immunogenic composition of the microparticles, and/or microemulsions of the invention, are also provided.

公开(公告)号：US08475808B2

公开(公告)日：2013-07-02

申请号：US10557427

申请日：2004-05-21

申请人： William Andrews ,  David Chien ,  Qui-Lim Choo ,  Stephen Coates ,  Doris Coit ,  Charles Harrington ,  Susan Hilt ,  Michael Houghton ,  Angelica Medina-Selby ,  Sergio Pichuantes ,  Yiu-Lian Fong

发明人： William Andrews ,  David Chien ,  Qui-Lim Choo ,  Stephen Coates ,  Doris Coit ,  Charles Harrington ,  Susan Hilt ,  Michael Houghton ,  Angelica Medina-Selby ,  Sergio Pichuantes ,  Yiu-Lian Fong

IPC分类号： A61K39/12 ,  C12Q1/70 ,  C12N15/86

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/545 ,  A61K2039/55566 ,  C07K2319/02 ,  C12N2770/24122 ,  C12N2770/24134 ,  G01N33/56983 ,  G01N33/6854 ,  G01N2333/18 ,  G01N2469/20 ,  Y02A50/394

摘要： Recombinant production of immunogenic West Nile Virus (WNV) proteins is described. These proteins, heterodimers comprising the proteins, fusions thereof, polynucleotides encoding the proteins, and combinations thereof, as well as antibodies produced therefrom, can be used in immunogenic compositions for preventing, treating and diagnosing WNV infection. Also described are highly sensitive ELISA and strip immunoassay methods for detecting the presence of WNV in biological samples.

摘要翻译： 描述了免疫原性西尼罗病毒（WNV）蛋白的重组产生。 包含蛋白质的这些蛋白质，其融合物，编码蛋白质的多核苷酸及其组合以及由其产生的抗体可用于预防，治疗和诊断WNV感染的免疫原性组合物中。 还描述了用于检测生物样品中WNV存在的高灵敏度ELISA和条带免疫测定方法。

公开(公告)号：US08431139B2

公开(公告)日：2013-04-30

申请号：US11434203

申请日：2006-05-16

申请人： John Telford ,  Vega Masignani ,  Maria Scarselli ,  Guido Grandi ,  Herve Tettelin ,  Claire Fraser

发明人： John Telford ,  Vega Masignani ,  Maria Scarselli ,  Guido Grandi ,  Herve Tettelin ,  Claire Fraser

IPC分类号： A61K39/09

CPC分类号： C07K14/315 ,  A61K38/00 ,  A61K39/00 ,  A61K39/092 ,  A61K2039/505 ,  A61K2039/53 ,  C07K16/1275 ,  C07K16/40 ,  C07K2319/00 ,  C12N9/1088 ,  C12Y205/01018 ,  Y02A50/464 ,  Y02A50/466

摘要： The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

摘要翻译： 本发明提供来自B族链球菌（无乳链球菌）和A型链球菌（化脓链球菌）的蛋白质，包括氨基酸序列和相应的核苷酸序列。 给出数据以显示蛋白质是疫苗，免疫原性组合物和/或诊断的有用抗原。 蛋白质也是抗生素的靶标。

公开(公告)号：US08415382B2

公开(公告)日：2013-04-09

申请号：US12205028

申请日：2008-09-05

申请人： Abran Costales ,  Teresa Hansen ,  Barry H. Levine ,  Christopher McBride ,  Daniel J. Poon ,  Savithri Ramurthy ,  Paul A. Renhowe ,  Cynthia M. Shafer ,  Sharadha Subramanian ,  Joelle Verhagen

发明人： Abran Costales ,  Teresa Hansen ,  Barry H. Levine ,  Christopher McBride ,  Daniel J. Poon ,  Savithri Ramurthy ,  Paul A. Renhowe ,  Cynthia M. Shafer ,  Sharadha Subramanian ,  Joelle Verhagen

IPC分类号： A61K31/44

CPC分类号： C07D401/12 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06 ,  C04B35/632 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

摘要： New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

摘要翻译： 提供了新的取代的苯唑化合物，抑制人或动物受试者中的Raf激酶活性的组合物和方法。 新化合物组合物可以单独使用或与至少一种另外的药物组合使用，用于治疗Raf激酶介导的病症，例如癌症。

公开(公告)号：US08388942B2

公开(公告)日：2013-03-05

申请号：US12150530

申请日：2008-04-29

申请人： Sidney N Wolfe ,  Bret A Shirley ,  Susan Babuka ,  Dennis Fordham ,  Irina Esikova

发明人： Sidney N Wolfe ,  Bret A Shirley ,  Susan Babuka ,  Dennis Fordham ,  Irina Esikova

IPC分类号： A61K38/21 ,  C07K14/565

CPC分类号： C07K14/565

摘要： Improved methods for purification and recovery of interferon-beta (IFN-β) and compositions comprising substantially monomeric IFN-β are provided. In one purification method, substantially purified IFN-β or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (HCl) solution. Renaturation of the protein occurs by dilution with a suitable buffer. A similar purification method absent the precipitation step is also provided. Following renaturation of the IFN-β, residual guanidine HCl is removed by diafiltration or dialysis with a pharmaceutically acceptable buffer to prepare pharmaceutical compositions comprising substantially monomeric IFN-β.

摘要翻译： 用于纯化和回收干扰素-β（IFN-和bgr）的改进方法和包含基本上单体的IFN- 被提供。 在一种纯化方法中，基本纯化的IFN- 或其变体沉淀，然后溶解在盐酸胍（HCl）溶液中。 蛋白质的复性通过用合适的缓冲液稀释而发生。 还提供了没有沉淀步骤的类似的纯化方法。 经IFN-α的复性后，通过渗滤或用药学上可接受的缓冲液进行透析来除去残余的胍盐，以制备基本上含有单体IFN-β的药物组合物。

公开(公告)号：US20130011405A1

公开(公告)日：2013-01-10

申请号：US13612070

申请日：2012-09-12

申请人： Li Long ,  Mohammad Luqman ,  Asha Yabannavar ,  Isabel Zaror ,  Bao-Lu Chen ,  Xiaofeng Lu ,  Sang Hoon Lee ,  Deborah Hurst ,  Sharon Lea Aukerman ,  Daniel E. Lopes de Menezes

发明人： Li Long ,  Mohammad Luqman ,  Asha Yabannavar ,  Isabel Zaror ,  Bao-Lu Chen ,  Xiaofeng Lu ,  Sang Hoon Lee ,  Deborah Hurst ,  Sharon Lea Aukerman ,  Daniel E. Lopes de Menezes

IPC分类号： A61K39/395 ,  A61P29/00 ,  A61P19/04 ,  A61P35/00 ,  A61P19/02 ,  A61P19/08 ,  A61P37/06 ,  A61P25/00 ,  A61P1/16 ,  A61P1/00 ,  A61P7/06 ,  A61P31/14 ,  A61P17/06 ,  A61P21/04 ,  A61P5/14 ,  A61P37/00 ,  A61P7/02 ,  A61P9/00 ,  A61P3/10 ,  A61P37/08 ,  A61P11/06 ,  A61P25/28 ,  C12N5/0781 ,  A61K39/44

CPC分类号： C07K16/2878 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6849 ,  A61K2039/505 ,  A61K2039/507 ,  A61N5/10 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

摘要： Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.

摘要翻译： 提供了用于治疗通过CD40表达细胞刺激CD40信号传导介导的疾病的组合物和方法。 所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CD40抗体或其抗原结合片段。 拮抗性抗CD40抗体或其抗原结合片段没有显着的激动剂活性，但当抗体结合表达人CD40的细胞上的CD40抗原时，其表现出拮抗剂活性。 抗CD40抗体或其抗原结合片段的拮抗作用有利地抑制人CD40表达细胞如B细胞的增殖和/或分化。